BATF2 Antibody
Description
Molecular and Functional Characteristics of BATF2
BATF2 is a 274-amino acid nuclear protein with a molecular weight of 29 kDa (human isoform) . Key features include:
-
Domain structure: Contains a basic leucine zipper (bZIP) domain for DNA binding and protein dimerization .
-
Gene location: Chromosome 11 in humans (Entrez Gene ID: 116071), chromosome 7 in mice (Entrez Gene ID: 74481) .
BATF2 regulates proinflammatory cytokine production (e.g., TNF, IL-12p40) in macrophages during bacterial infections like Klebsiella pneumoniae and modulates immune pathologies in diseases such as tuberculosis and colitis .
BATF2 Antibody Applications
Commercially available BATF2 antibodies are widely used in research, with key applications and performance data:
Immune Regulation
-
BATF2 enhances proinflammatory cytokine responses (e.g., TNF, CCL5) in macrophages during Klebsiella pneumoniae infection via TRIF and type I interferon signaling .
-
Deficiency in BATF2 increases bacterial burden in murine lung infection models, impairing early host defense .
Disease Contexts
Product Specs
Target Background
The AP-1 family transcription factor BATF2 plays a critical role in regulating the differentiation of lineage-specific immune cells. Following infection, it participates in the differentiation of CD8+ thymic conventional dendritic cells. BATF2 forms heterodimers with JUN family proteins, binding to the DNA sequence 5'-TGA[CG]TCA-3' to modulate gene expression. Importantly, BATF2 selectively suppresses CCN1 transcription, thereby inhibiting downstream cell proliferation signals and suppressing anchorage-independent growth and invasion in various cancers, including breast cancer, malignant glioma, and metastatic melanoma. This suppressive effect is likely achieved by interfering with AP-1 binding to the CCN1 promoter.
BATF2 and Related Gene Research:
- Medulloblastoma: BATF2 modulation after zebularine treatment indicated poor prognosis, with low BATF2 levels correlating with relapse and unfavorable outcomes. (PMID: 27785591)
- Myeloid Differentiation and Hematopoietic Stem Cells (HSCs): Gain- and loss-of-function studies revealed BATF2's role in myeloid differentiation in both murine and human systems. Chronic infection depletes HSCs, with BATF2 mediating infection-induced HSPC terminal differentiation. (PMID: 27926863)
- Glioblastoma and Bevacizumab: BATF2's role in tumors suggests its potential as a therapeutic target to counteract bevacizumab-induced epithelial-mesenchymal transition in glioblastoma. (PMID: 28739720)
- Heterochromatin Stability: BATF2 may exert selective pressure on the recombination machinery via a repetitive motif-based mechanism to maintain heterochromatin stability. (PMID: 26977016)
- Infectious Diseases and Cancer: BATF2 plays a significant role in both infectious diseases and cancer. (PMID: 26376615)
- B Lymphoma and Dexamethasone: SARI, a novel glucocorticoid receptor target gene, is upregulated by dexamethasone, contributing to its cytotoxic effects on B lymphoma cells. (PMID: 26808579)
- Prostate Cancer and Interferon-beta: SARI may play a significant role in prostate cancer development. Interferon-beta may inhibit prostate cancer growth and induce apoptosis through SARI upregulation. (PMID: 26339361)
- Esophageal Squamous Cell Carcinoma (ESCC): BATF2 acts as a tumor suppressor, serving as a prognostic biomarker and potential therapeutic target for ESCC. (PMID: 26135942)
- Colorectal Cancer Prognosis: BATF2 status may predict colorectal cancer prognosis. (PMID: 26022579)
- Colorectal Cancer and HGF/MET Signaling: BATF2, a tumor suppressor, negatively regulates HGF/MET signaling in colorectal cancer. (PMID: 25762344)
- Oral Tongue Squamous Cell Carcinoma: BATF2 functions as a tumor suppressor, serving as a prognostic biomarker and potential therapeutic target. (PMID: 24252932)
- Non-Small Cell Lung Cancer: SARI expression predicts poor prognosis and may serve as a biomarker and therapeutic target. (PMID: 24133583)
- Cancer-Specific Apoptosis and SARI: MDA-7/IL-24 induces cancer-specific apoptosis through SARI induction. (PMID: 24282278)
- Lung Adenocarcinoma and Epithelial-to-Mesenchymal Transition (EMT): Loss of SARI expression initiates EMT, characterized by E-cadherin repression and vimentin upregulation. (PMID: 23049725)
- Chronic Myelogenous Leukemia (CML) and BCR-ABL: BCR-ABL downregulates SARI mRNA expression in K562 cells, suggesting SARI as a potential therapeutic target in CML. (PMID: 21867603, PMID: 21892628)
- Hepatocellular Carcinoma: Decreased BATF2 expression is associated with hepatocellular carcinoma. (PMID: 20473897)
- CCN1 and Transformation Progression: SARI inhibits AP-1, negatively regulating CCN1-mediated transformation progression. (PMID: 20531301)
